Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia

Blood

Volumn 100, Issue 1, 2002, Pages 52-58

  Coustan Smith, Elaine ^a   Sancho, Jose ^a   Behm, Frederick G ^a   Hancock, Michael L ^a   Razzouk, Bassem I ^a   Ribeiro, Raul C ^a   Rivera, Gaston K ^a   Rubnitz, Jeffrey E ^a   Sandlund, John T ^a   Pui, Ching Hon ^a   Campana, Dario ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; HYDROCORTISONE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CELL STRUCTURE; CHILD; CHILDHOOD DISEASE; FEMALE; FLOW CYTOMETRY; HUMAN; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0036660158     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-01-0006     Document Type: Article

References (34)

1. Kaspers GJ, Veerman AJ, Pieters R, et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood. 1997;90:2723-2729.
2. Mahmoud HH, Rivera GK, Hancock ML, et al. Low leukocyte counts with blast cells in cerebro-spinal fluid of children with newly diagnosed acute lymphoblastic leukemia. N Engl J Med. 1993;329:314-319.
3. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med. 1998;338:499-505.
4. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286:487-491.
5. Felix CA, Lange BJ, Chessells JM. Pediatric Acute Lymphoblastic Leukemia: Challenges and Controversies in 2000. American Society of Hematology Education Program, Washington, DC: American Society of Hematology; 2000:285-302.
6. Pui CH, Sallan S, Relling MV, Masera G, Evans WE. International Childhood Acute Lymphoblastic Leukemia Workshop: Sausalito, CA, 30 November-1 December 2000. Leukemia. 2001;15:707-715.
7. Pui CH, Campana D, Evans WE. Childhood acute lymphoblastic leukemia - current status and future perspectives. Lancet Oncol. 2001;2:597-607.
8. Riehm H, Reiter A, Schrappe M, et al. Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83) [in German]. Klin Padiatr. 1987;199:151-160.
9. Gajjar A, Ribeiro R, Hancock ML, et al. Persistence of circulating blasts after 1 week of multi-agent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood. 1995;86:1292-1295.
10. Lilleyman JS, Gibson BE, Stevens RF, et al. Clearance of marrow infiltration after 1 week of therapy for childhood lymphoblastic leukaemia: clinical importance and the effect of daunorubicin. The Medical Research Council's Working Party on Childhood Leukaemia. Br J Haematol. 1997;97:603-606.
11. -) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood, 1998;92:2730-2741.
12. Dordelmann M, Reiter A, Borkhardt A, et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood. 1999;94:1209-1217.
13. Miller DR, Coccia PF, Bleyer WA, et al. Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group. J Clin Oncol. 1989;7:1807-1815.
14. Steinherz PG, Gaynon PS, Breneman JC, et al. Cytoreduction and prognosis in acute lymphoblastic leukemia - the importance of early marrow response: report from the Childrens Cancer Group. J Clin Oncol. 1996;14:389-398.
15. Sandlund JT, Harrison P, Rivera GK, et al. Persistence of lymphoblasts in bone marrow on day 15 and day 22-25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia. Blood. 2002;100:_-_.
16. Campana D, Pui CH. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood. 1995;85:1416-1434.
17. Pui CH, Campana D. New definition of remission in childhood acute lymphoblastic leukemia. Leukemia. 2000;14:783-785.
18. Szczepanski T, Orfao A, van der Velden VH, San Miguel JF, van Dongen JJ. Minimal residual disease in leukaemia patients. Lancet Oncol. 2001;2:409-417.
19. Gaynon PS, Desai AA, Bostrom BC, et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer. 1997;80:1717-1726.
20. Campana D, Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry. 1999;38:139-152.
21. Neale GA, Coustan-Smith E, Pan Q, et al. Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia. 1999;13:1221-1226.
22. Coustan-Smith E, Behm FG, Sanchez J, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet. 1998;351:550-554.
23. Coustan-Smith E, Sancho J, Hancock ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood. 2000;96:2691-2696.
24. Campana D, Behm FG. Immunophenotyping of leukemia. J Immunol Methods. 2000;243:59-75.
25. Raimondi SC, Mathew S, Pul CH. Cytogenetics as a diagnostic aid for childhood hematological disorders. Conventional cytogenetic techniques, fluorescence in situ hybridization, comparative genomic hybridization, In: Hanausek M, Walaszek Z, eds. Methods in Molecular Biology. Totowa, NJ: Humana Press; 1998:209-227.
26. Scurto P, Hsu RM, Kane JR, et al. A multiplex RTPCR assay for the detection of chimeric transcripts encoded by the risk-stratifying translocations of pediatric acute lymphoblastic leukemia. Leukemia. 1998;12:1994-2005.
27. Pui CH, Rivera GK, Hancock ML, etal. Risk-adapted treatment for ALL - findings from St Jude Children's Research Hospital. In: Buchner T, Hiddemann W, Wormann B, Schellong G, Ritter J, Creutzig U, eds. Acute Leukemias VI: Prognostic Factors and Treatment Strategies. Berlin, Germany: Springer-Verlag; 1997:629-637.
28. Pui CH, Mahmoud HH, Rivera GK, et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood. 1998;92:411-415.
29. Chen JS, Coustan-Smith E, Suzuki T, et al. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. Blood. 2001;97:2115-2120.
30. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley; 1980.
31. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
32. Panzer-Grumayer ER, Schneider M, Panzer S, Fasching K, Gadner H. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood. 2000;95:790-794.
33. Rimsza LM, Larson RS, Winter SS, et al. Benign hematogone-rich lymphoid proliferations can be distinguished from B-lineage acute lymphoblastic leukemia by integration of morphology, immunophenotype, adhesion molecule expression, and architectural features. Am J Clin Pathol. 2000;114:66-75.
34. McKenna RW, Washington LT, Aquino DB, Picker LJ, Kroft SH. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood. 2001;98:2498-2507.